Wolfgang Miesbach/LinkedIn
Apr 28, 2026, 05:28
Wolfgang Miesbach: How Can the Sustainable Funding of Transformative Gene Therapies Be Ensured?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Approved Gene Therapy. For Free. In 2026.
Regeneron’s Otarmeni (lunsotogene parvec‑cwha) – the first FDA‑approved gene therapy for genetic hearing loss – will be provided at no cost to clinically eligible patients in the United States.
Under a ‘Most Favored Nation’ (MFN)–style agreement with the U.S. government, linking U.S. prices to the lowest levels observed in comparable high‑income countries, Regeneron has committed to:
- Providing Otarmeni at no cost to eligible U.S. patients (with treatment logistics and administration costs covered through established payer mechanisms).
- Aligning Medicaid pricing – as well as future U.S. launch prices for selected medicines – with international benchmark levels.
- Medicaid is the U.S. public insurance program covering tens of millions of individuals, including low‑income populations, children, people with disabilities, and older adults.
- Expanding U.S.-based manufacturing and repatriating foreign revenues within an ‘America‑first’ pricing framework.
One big question remains:
How can the sustainable funding of transformative gene therapies be ensured in a manner that is equitable for both patients and healthcare systems?”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments